EMA accepts Biocon, Mylan biosimilar for review

Biocon and Mylan NV said Mylan’s application to market biosimilar Trastuzumab has been accepted by the European Medicines Agency (EMA) for review. The biosimilar Trastuzumab is used to treat certain

Read more: http://www.thehindu.com/business/Industry/ema-accepts-biocon-mylan-biosimilar-for-review/article9032517.ece?utm_source=RSS_Feed&utm_medium=RSS&utm_campaign=RSS_Syndication

Click here for reuse options!
Copyright 2017 Social Zazz